Conv. Plasma
Nigella Sativa
Peg.. Lambda

All favipiravir studies
Meta analysis
Home COVID-19 treatment researchFavipiravirFavipiravir (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 96% Improvement Relative Risk ICU admission 21% Hospitalization time 16% Favipiravir  Tawfik et al.  LATE TREATMENT Is late treatment with favipiravir beneficial for COVID-19? Retrospective 165 patients in Saudi Arabia (June - November 2020) Lower mortality (p<0.0001) and shorter hospitalization (p<0.0001) Tawfik et al., Advances in Virology, Jun 2022 Favors favipiravir Favors control

Effectiveness of Early Favipiravir Therapy in Hospitalised COVID-19 Patients

Tawfik et al., Advances in Virology, doi:10.1155/2022/9240941
Jun 2022  
  Source   PDF   All Studies   Meta AnalysisMeta
Retrospective 103 hospitalized patients in Saudi Arabia, showing lower mortality with favipiravir in unadjusted results, and greater efficacy for treatment within 3 days of admission. This study is excluded in the after exclusion results of meta analysis: unadjusted results with minimal group details.
risk of death, 96.5% lower, RR 0.04, p < 0.001, treatment 1 of 103 (1.0%), control 17 of 62 (27.4%), NNT 3.8.
risk of ICU admission, 21.0% lower, RR 0.79, p = 0.45, treatment 21 of 103 (20.4%), control 16 of 62 (25.8%), NNT 18.
hospitalization time, 15.8% lower, relative time 0.84, p < 0.001, treatment mean 9.6 (±1.2) n=102, control mean 11.4 (±1.7) n=58.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Tawfik et al., 29 Jun 2022, retrospective, Saudi Arabia, peer-reviewed, mean age 60.1, 8 authors, study period 3 June, 2020 - 3 November, 2020.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFavipiravirAll
Effectiveness of Early Favipiravir Therapy in Hospitalised COVID-19 Patients
Abdulrahman Tawfik, Abdulrahman Alzahrani, Sami Alharbi, Jamal Almitairi, Arwa Alzahrani, Mohammed Ali Alshehri, Mohammed S Aldughaim, Hani Alothaid
Advances in Virology, doi:10.1155/2022/9240941
COVID-19 is a disease caused by a novel coronavirus with no speci c, standard treatment. We investigated the clinical data of COVID-19 patients admitted to King Fahad Specialist Hospital (KFSH) in Buraydah by comparing the patients who were treated early with favipiravir (within 3 days of admission) to patients who were treated after three days of admission or not treated. 165 patients were con rmed with PCR tests and admitted to KFSH for treatment. Comorbidities contributed signi cantly to increasing the length of stay in hospital at 11.4 ± 0.8 days compared to patients with no comorbidities at 8.6 ± 0.9 days (p 0.041). A total of 103 patients were treated with favipiravir, and we found that early treatment with favipiravir (within 3 days) reduced the length of stay in hospital signi cantly (8.8 ± 1.4 days) compared to patients who were treated after 3 days (13.3 ± 4.6 days) (p 0.0015). Moreover, patients with comorbidities in both early and late treatment groups had signi cantly higher average lengths of stay in hospital (11.2 ± 0.9 days) compared to patients with no comorbidities (7.9 ± 0.7 days) (p 0.017). Interestingly, patients treated early with favipiravir (with comorbidities and without) stayed fewer days in hospital compared to those with late treatment (p 0.021; a di erence of 4.5 ± 1.9 days; and p 0.018; a di erence of 4.2 ± 1.7 days, respectively). In conclusion, our analysis indicates that early treatment with favipiravir can reduce the length of stay in hospital and improve clinical manifestations of COVID-19 patients.
Disclosure Abdulrahman Tawfik and Abdulrahman Alzahrani are cofirst authors. Conflicts of Interest e authors declare no conflicts of interest.
Biswas, Rahaman, Biswas, Haque, Ibrahim, Association of sex, age, and comorbidities with mortality in COVID-19 patients: a systematic review and meta-analysis, Intervirology
Bonanad, García-Blas, Tarazona-Santabalbina, e effect of age on mortality in patients with COVID-19: a meta-analysis with 611,583 subjects, Journal of the American Medical Directors Association
Cai, Yang, Liu, Experimental treatment with favipiravir for COVID-19: an open-label control study, Engineering Times
Chen, Zhang, Huang, Favipiravir versus arbidol for clinical recovery rate in moderate and severe adult COVID-19 patients: a prospective, multicenter, open-label, randomized controlled clinical trial, Frontiers in Pharmacology
Doi, Hibino, Hase, A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19, Antimicrobial Agents and Chemotherapy
Ford, Vitoria, Rangaraj, Norris, Calmy et al., Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment, Journal of the International AIDS Society
Furuta, Takahashi, Shiraki, T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections, Antiviral Research
Han, Ma, Li, Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors, Emerging Microbes & Infections
Helmy, Fawzy, Elaswad, Sobieh, Kenney et al., e COVID-19 pandemic: a comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control, Journal of Clinical Medicine
Joshi, Parkar, Ansari, Role of favipiravir in the treatment of COVID-19, International Journal of Infectious Diseases: International Journal of Infectious Diseases
Karatas, Aksoy, Ozaslan, Association of early favipiravir use with reduced COVID-19 fatality among hospitalized patients, Infection and Chemotherapy
Magleby, Westblade, Trzebucki, Impact of SARS-CoV-2 viral load on risk of intubation and mortality among hospitalized patients with coronavirus disease 2019, Clinical Infectious Diseases
Wang, Cao, Zhang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Research
Wu, Li, Shi, Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19), Journal of Internal Medicine
Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China, Journal of the American Medical Association
Yanai, Favipiravir: a possible pharmaceutical treatment for COVID-19, Journal of Endocrinology and Metabolism
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop